Phospho-specific flow: fixating on the target.
Targeted therapies are all the rage in oncology research these days. The problem remains as to how to confirm that the target is actually being hit in vivo. This report describes the application of phospho-specific flow cytometry to establish in vivo target inhibition in real time.
Department of Oncology, Johns Hopkins University, Baltimore, MD, USA. levisma@jhmi.edu
Mark
M
Levis
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000627:therapeutic use; D005047:Etoposide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000378:metabolism*; D008297:Male; D008942:Mitoxantrone / Q000627:therapeutic use; D038601:Ribosomal Protein S6 / Q000378:metabolism*; D020123:Sirolimus / Q000627:therapeutic use*; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors*
D038601:Ribosomal Protein S6; D003561:Cytarabine; D005047:Etoposide; D008942:Mitoxantrone; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus